PCSK9 inhibitors × lipids

RetractedSynthesisBioMed research international2021

A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia.

Xiaoyue Ge et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 2021

Randomised comparison

Probably lowered lipids

−49.1percentage points−55.8 to −42.5

As reported

difference −49.14 %, 95% CI −55.8 to −42.5

One number in the abstract

the abstract, start to end

LDL-C level by the greatest margin, WMD -49.14%, 95% CI: -55.81 to -42.47%, on

← favours treatmentfavours comparator →
could be chance
Lipids
−49.14−55.8 to −42.5
PCSK9 inhibitorsLipids

PCSK9 inhibitors × lipidshelps?settled

unlikelylikely
0.93not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 5

9 papers cite it

2021
2022
2023
2024
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 34754882